25/06/2026 09:20

Cochlear Ltd (ASX: COH) $113.45

COH has delivered two painful downgrades in 2026, taking the stock down 56% just this year. We covered Aprils savage downgrade here, coming to the easy conclusion that this was a stock best avoided for the foreseeable future, especially if we remember the market adage, “Buy the Third Downgrade.” Two downgrades in three months do not breed confidence in a market that’s very comfortable throwing stocks into the naughty corner and forgetting about them.

Read more

23/04/2026 09:17

Cochlear Ltd (ASX:COH) $99.58

We covered the Cochlear dramatic downgrade in detail yesterday Here. As we said at the time, COH was whacked after delivering one of the ugliest downgrades in a long time, especially when it was only two months ago that they said earnings would likely be at the lower end of guidance, not 30% below! - credibility straight out of the window.

Read more

22/04/2026 17:34

Cochlear (ASX:COH) $99.58

COH -40.7%: was whacked today after delivering one of the ugliest downgrades we’ve seen from a large cap healthcare name in some time. The hearing implant leader slashed FY26 underlying net profit guidance to $290–330m, down from the previous $435–460m range, with the stock plunging 40% on the day - its worst sell-off since listing.

Read more

22/04/2026 10:45

Cochlear Ltd (ASX:COH) $104.50

Cochlear (ASX:COH) has plunged almost 40%, the most in more than 30-years,after downgrading net profit guidance by ~25%.

Read more

11/03/2026 09:20

Cochlear Ltd (COH) $182.52

COH has more than halved from its 2024 high, and it now trades on its lowest valuation of the decade, despite revenue continuing to climb from $1.6bn in 2022 to a forecast $2.7bn by 2027. However, the market showed little patience during the recent reporting season, with the hearing device maker falling ~25% in February after a comparatively modest ~5% 1H profit miss.

Read more

04/11/2025 09:26

Cochlear Ltd (COH) $283.89

At the end of October, COH reaffirmed its FY26 earnings guidance, for an 11% to 17% increase in underlying net profit from last year. Device demand across both cochlear implants and Acoustics looks strong, while Services expectations have been reset over the last 12-18 months, which puts the stock firmly in the “buy the dip” camp for MM.

Read more

16/09/2025 09:42

Cochlear Ltd (COH) $302.72

COH had a quiet report last month after flagging much of the result in June which at the time saw the stock surge back towards $300. The company is pinning its hopes on the rollout of a new hearing implant called Nucleus Nexa to boost earnings after this year’s disappointing performance, although net profit still grew 9%.

Read more

08/07/2025 09:35

Cochlear Ltd (COH) $300.74

COH surged higher in June ironically after headlines of “Cochlear cuts guidance”. The hearing company flagged an underlying net profit for the 12 months through June of $390-400mn, down by around 6% compared to its February numbers.

Read more

13/02/2025 09:29

Cochlear Ltd (COH) $306.69

Hearing implant business COH was the best-performing healthcare name on Wednesday, closing up +1.6%. However, we remain concerned that the share price isn’t factoring in the risks of Moderna’s potential phase III data for a vaccine against human cytomegalovirus, which causes infant deafness.

Read more

04/10/2024 09:24

Cochlear Ltd (COH) $287.70

Read more